Literature DB >> 7667368

Nicotine-induced conditioned place preference and conditioned place aversion in mice.

F O Risinger1, R A Oakes.   

Abstract

The motivational effects of nicotine were examined in mice using an unbiased place conditioning design. Swiss-Webster mice received four 15-min parings of a tactile stimulus with different doses of nicotine (0.25-2.0 mg/kg, IP). A different tactile stimulus was paired with saline injections. During conditioning, nicotine produced locomotor depression at the 2.0-mg/kg dose, with the greatest reduction in activity occurring during the latter part of each nicotine conditioning session. After four trials, nicotine produced increases in locomotor activity during the initial part of the nicotine sessions at doses 0.5 mg/kg or above. Upon testing, nicotine-induced conditioned place preference was noted in mice receiving 0.5 mg/kg nicotine. Conditioned place aversion was noted in mice receiving 2.0 mg/kg nicotine whereas doses of 0.25 and 1.0 mg/kg produced no conditioning. These results indicate that nicotine has dose-dependent rewarding and aversive effects measured in an unbiased place conditioning paradigm using mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667368     DOI: 10.1016/0091-3057(95)00007-j

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  46 in total

Review 1.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

2.  Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL/6 and DBA/2 inbred strains.

Authors:  C Orsini; A Bonito-Oliva; D Conversi; S Cabib
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 3.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

4.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Variability in nicotine conditioned place preference and stress-induced reinstatement in mice: Effects of sex, initial chamber preference, and guanfacine.

Authors:  Angela M Lee; Cali A Calarco; Sherry A McKee; Yann S Mineur; Marina R Picciotto
Journal:  Genes Brain Behav       Date:  2019-08-13       Impact factor: 3.449

6.  Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.

Authors:  Graciela N Balerio; Ester Aso; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

7.  Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum.

Authors:  Raffaella Isola; Hailin Zhang; Gopi A Tejwani; Norton H Neff; Maria Hadjiconstantinou
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

8.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

9.  The endogenous cannabinoid system modulates nicotine reward and dependence.

Authors:  Lisa L Merritt; B R Martin; C Walters; A H Lichtman; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2008-05-01       Impact factor: 4.030

10.  The effects of nicotine on ethanol-induced conditioned taste aversions in Long-Evans rats.

Authors:  Jennifer A Rinker; Gregory D Busse; Peter G Roma; Scott A Chen; Christina S Barr; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2008-01-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.